Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex announced positive long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU), showing that up to 64% of patients remained angioedema-free seven months after treatment completion. The drug demonstrated rapid, significant, and durable improvements in angioedema symptoms, with potential to shift CSU treatment from symptom control to disease modification. Two Phase 3 trials enrolling 1,939 patients are ongoing with topline data expected in Q4 2026.

06/14/2026, 10:21 AM • GlobeNewswire

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex announced positive Phase 1 results for CDX-622, a novel bispecific antibody targeting soluble SCF and TSLP for inflammatory diseases. The drug demonstrated rapid, dose-dependent reductions in serum tryptase indicative of mast cell depletion and was well-tolerated at all dose levels. CDX-622 is now being studied in Phase 1b for mild to moderate asthma, with plans for additional proof-of-concept studies in allergic rhinitis and food allergy.

06/14/2026, 5:15 AM • GlobeNewswire

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Celldex Therapeutics successfully closed an underwritten public offering of 11,896,750 shares of common stock at $29.00 per share, generating approximately $345 million in gross proceeds. The underwriters exercised their full option to purchase an additional 1,551,750 shares. The offering was managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor as joint bookrunning managers.

04/06/2026, 10:53 AM • GlobeNewswire

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

Celldex Therapeutics priced an underwritten public offering of 10.3 million shares at $29.00 per share, expecting to raise approximately $300 million in gross proceeds. The company plans to use the funds for commercial readiness and launch of barzolvolimab for CSU treatment, clinical development of product candidates, and expansion of its bispecific antibody platform.

04/01/2026, 9:48 PM • GlobeNewswire

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Celldex presented Phase 2 data showing barzolvolimab retreatment achieves similar efficacy to initial treatment in cold urticaria and symptomatic dermographism patients, with 62% and 60% complete response rates respectively. The data supports an intermittent treatment paradigm and barzolvolimab's profile as a first-in-class therapy. Phase 3 trials (EMBARQ-ColdU and SD) are currently enrolling patients.

03/01/2026, 9:45 AM • GlobeNewswire

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Celldex presented positive Phase 2 data for barzolvolimab, a novel mast cell-targeting monoclonal antibody, showing sustained off-treatment efficacy in chronic spontaneous urticaria (CSU) with 71% of patients achieving complete response after 52 weeks of treatment and 50% maintaining complete response 7 months post-treatment. The company also demonstrated improved quality of life and urticaria control in cold urticaria and symptomatic dermographism patients. Phase 3 enrollment in CSU was completed six months ahead of schedule with topline data expected in Q4 2026.

02/27/2026, 2:45 PM • GlobeNewswire

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

The global CIndU market is experiencing significant growth driven by advancements in diagnostic tools, biologic therapies, and increasing awareness of immune mechanisms, with emerging personalized medicine approaches promising improved patient outcomes.

08/27/2025, 4:50 AM • GlobeNewswire